

Neurogenic and Behavioural Effects Induced by Duloxetine (Cymbalta) in Rats Exposed to Chronic Restraint Stress Model

A Thesis

Submitted for Partial Fulfillment of Master Degree
in Pharmacology

By

Radwa Sayed Raafat Taha

M.B., B.Ch. (٢٠٠٧), Demonstrator in Department of
Pharmacology & Therapeutics
Faculty of Medicine- Ain Shams University

Supervised by

Ass. Prof. Salwa Abdel Khalek Nawishy

Ph.D. (London)

Assistant Prof. of Clinical Psychopharmacology, Department of
Pharmacology & Therapeutics- Faculty of Medicine- Ain Shams
University

Ass. Prof. Sawsan Aboul-Fotouh El-Said

Assistant Prof. of pharmacology, Department of Pharmacology
& Therapeutics- Faculty of medicine- Ain shams university

**Faculty of Medicine
Ain Shams University**

٢٠١٣

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgements

All praises to Allah, the most gracious and the most merciful.

*I would like to express my thanks to **Dr. Salwa Abdel Khalek Nawishy**, Assistant Professor of Pharmacology, Faculty of medicine, Ain Shams University for her moral support, continuous encouragement, valuable assistance and constructive criticism.*

*I am also greatly indebted to **Dr. Sawsan Aboul Fotouh El-Said**, Assistant Professor of Pharmacology, Faculty of medicine, Ain Shams University, for her constant support, patience and encouragement for this work.*

*I wish to express my appreciation and gratitude to **Dr. Ahmed Abd El-Salam**, professor of Pharmacology, Faculty of medicine, Ain Shams University, for his sincere help and valuable support in this work.*

I would like to thank Mohamed El-Tabal, sixth year medical student, faculty of medicine, Ain Shams University for his help in preparing the open field test software program.

I am also grateful to my senior staff, colleagues in the Department of Pharmacology, Faculty of medicine, Ain Shams University, and to all who offered me any help to fulfill this work.

I also extend special thanks to my family members for their patience and support through this study.

Contents

Title	Page
List of Figures	I
List of Tables	VII
List of Abbreviation	IX
Chapter (١): Introduction	
.....	١
<i>Aim of the Work</i>	٤٧
Chapter (٢): Materials and Methods	
.....	٤٨
Chapter (٣): Results	٧٠
Chapter (٤): Discussion	١٣٤
<i>English Summary</i>	١٥٤
<i>References</i>	١٥٩
<i>Arabic Summary</i>	—

Abstract

There is a growing evidence that increased neurogenesis and brain-derived neurotrophic factor (BDNF) can be relevant to mood disorders. The modulation of neurogenesis and BDNF biosynthesis following prolonged antidepressant treatment may contribute to neuroplastic changes required for behavioural response.

The objective of this study is to assess the behavioural and neurogenic effects of duloxetine on BDNF in the rat brain. Duloxetine was administered in doses 10, 20 and 30 mg/kg/day. After 21 days, all rats were subjected to behavioural tests namely forced swimming test (FST) and open field test (OFT). Measurement of serum corticosterone level, brain derived neurotrophic factor concentration in the prefrontal cortex and the hippocampus as well as histological study was carried out. The results showed that duloxetine (10, 20 and 30 mg/kg/day) produced a statistically significant ($p < 0.001$) reduction in the serum corticosterone concentration. Duloxetine in doses of 20 and 30 mg/kg/day produced a statistically significant ($p < 0.001$) elevation of the BDNF concentration in the prefrontal cortex of the stressed rats while the elevation was statistically insignificant ($p > 0.05$) with duloxetine in a dose of 10 mg/kg/day. Duloxetine in the three doses (10, 20 and 30

mg/kg/day) caused a statistically significant ($p < 0.05$) elevation of BDNF concentration in the hippocampus of the stressed rats. Moreover, duloxetine treated rats improved the stress-induced cellular changes. It also reversed the stress induced behavioural changes. Duloxetine induced a statistically significant reduction in the immobility time ($p < 0.001$), a statistically significant increase in swimming ($p < 0.001$) and climbing time ($p < 0.001$) in the FST. It also showed a statistically significant decrease in the frequency of rearing ($p < 0.05$) and the number of total crossed squares ($p < 0.05$) in the OFT in the chronically stressed Wistar rats. Moreover, chronic duloxetine treatment showed a statistically significant positive correlation between the BDNF level in the PFC and the climbing time ($r^2 = 0.47$, $p = 0.004$). The BDNF level in the PFC and swimming time showed statistically significant negative correlation ($r^2 = -0.44$, $p = 0.017$).

In conclusion, chronic duloxetine administration showed possible neurogenic effects on the rat prefrontal cortex and the hippocampus. This finding reflects an improved ability to cope under stressful conditions.

Keywords: Brain derived neurotrophic, duloxetine, chronic restraint stress, forced swimming test, open field test.

List of Figures

Figure	Title	Page
Fig. (١)	Protein standard curve	٦١
Fig. (٢)	A bar chart illustrating the effects of chronic treatment with duloxetine (١٠, ٢٠ and ٢٧ mg/kg/day, p.o. for ٢١ days) on serum corticosterone concentrations (ng/ml) in Wistar rats exposed to chronic restraint stress (CRS).	٧٣
Fig. (٣)	A bar chart illustrating the effects of chronic treatment with duloxetine (١٠, ٢٠ and ٢٧ mg/kg/day, p.o. for ٢١ days) on BDNF concentration in tissue homogenate of prefrontal cortex in Wistar rats exposed to chronic restraint stress (CRS).	٧٧
Fig. (٤)	A bar chart illustrating the effects of chronic treatment with duloxetine (١٠, ٢٠ and ٢٧ mg/kg/day, p.o. for ٢١ days) on BDNF concentration (ug/mg protin) in tissue homogenate of hippocampus in Wistar rats exposed to chronic restraint stress (CRS).	٨١
Fig. (٥)	A Photomicrograph of the prefrontal cortex of the control group showing the molecular layer, external granular layer, external pyramidal layer, internal granular layer, internal pyramidal layer and multiform layer.	٨٣
Fig. (٦)	A photomicrograph of the prefrontal cortex of the control group showing that most of the cells have vesicular nuclei.	٨٣

Figure	Title	Page
Fig. (v)	A photomicrograph of the prefrontal cortex of the control group showing Nissl's granules content in the cytoplasm of the cells of the cerebral cortex.	٨٥
Fig. (٨)	A photomicrograph of the prefrontal cortex of the stressed non-treated group showing that most of the cells have dark cytoplasm and pyknotic nuclei. They are also shrunken and surrounded by perineural space.	٨٧
Fig. (٩)	A photomicrograph of the prefrontal cortex of the stressed non-treated group showing apparent decrease in Nissl's granules content in the cytoplasm of the majority of cells of the cerebral cortex compared with the control group.	٨٧
Fig. (١٠)	A photomicrograph of the prefrontal cortex of the stressed group treated with duloxetine (١٠ mg/kg/day) showing that many cells have shrunken cytoplasm and pyknotic nuclei and surrounded by perineural space. Few cells are normal with vesicular nuclei.	٨٩
Fig. (١١)	A photomicrograph of the prefrontal cortex of the stressed group treated with duloxetine (١٠ mg/kg/day) showing some cells that exhibit an increase in the content of Nissl's granules inside the cells.	٩١
Fig. (١٢)	A photomicrograph of the prefrontal cortex of the stressed group treated with duloxetine (٢٠ mg/kg/day) showing that most of the cells have vesicular nucleus and expanded cytoplasm.	٩٣

Figure	Title	Page
Fig. (١٣)	A photomicrograph of the prefrontal cortex of the stressed group treated with duloxetine (٢٠ mg/kg/day) showing apparent increase in the content of Nissl's granules inside the cells.	٩٣
Fig. (١٤)	A photomicrograph of the prefrontal cortex of the stressed group treated with duloxetine (٢٧ mg/kg/day) showing that many cells are normal with vesicular nuclei.	٩٥
Fig. (١٥)	A photomicrograph of the prefrontal cortex of the stressed group treated with duloxetine ٢٧ mg/kg/day showing apparent increase in the content of Nissl's granules inside the cells.	٩٥
Fig. (١٦)	A photomicrograph of the control group showing the hippocampal subdivisions CA١, CA٢ and CA٣.	٩٧
Fig. (١٧)	A photomicrograph of the CA٣ area of the hippocampus of the control group showing the pyramidal cell layer. The pyramidal cell layer is formed of closely packed cells with large vesicular nuclei and prominent nucleoli.	٩٧
Fig. (١٨)	A photomicrograph of the CA٣ area of the hippocampus of the control group showing that the cytoplasm of the pyramidal cells is studded with Nissl's granules.	٩٩
Fig. (١٩)	A photomicrograph of the hippocampus of the stressed non-treated group in the CA٣ region showing few pyramidal cells.	١٠١

Figure	Title	Page
Fig. (٢٠)	A photomicrograph of the hippocampal CA٣ region of the stressed non-treated group showing apparent decrease in the Nissl's granules content in the cytoplasm of pyramidal cells.	١٠١
Fig. (٢١)	A photomicrograph of the hippocampal CA٣ region of the stressed group treated with duloxetine (١٠ mg/kg/day) showing that some pyramidal cells appear with vesicular nuclei.	١٠٣
Fig. (٢٢)	A photomicrograph of the hippocampal CA٣ region of the stressed group treated with duloxetine (١٠ mg/kg/day) showing apparent increase in Nissl's granule content in the cytoplasm of the pyramidal cells.	١٠٣
Fig. (٢٣)	A photomicrograph of the hippocampal CA٣ region of the stressed group treated with duloxetine (٢٠ mg/kg/day) showing apparent increase in the pyramidal cell number that shows vesicular nuclei.	١٠٥
Fig. (٢٤)	A photomicrograph of the hippocampal CA٣ region of the stressed group treated with duloxetine (٢٠ mg/kg/day) showing apparent increase in Nissl's granule content in the cytoplasm of the pyramidal cells.	١٠٥
Fig. (٢٥)	A photomicrograph of the hippocampal CA٣ region of the stressed group treated with duloxetine (٢٧ mg/kg/day) showing some cells with vesicular nuclei	١٠٧
Fig. (٢٦)	A photomicrograph of the hippocampal	١٠٧

Figure	Title	Page
	CA γ region of the stressed group treated with duloxetine (25 mg/kg/day) showing apparent increase in Nissl's granule content in the cytoplasm of the pyramidal cells	
Fig. (27)	A bar chart illustrating effects of chronic treatment with duloxetine (10, 20 and 25 mg/kg/day, p.o. for 21 days) on FST immobility time (sec.) in Wistar rats exposed to chronic restraint stress (CRS).	111
Fig. (28)	A bar chart illustrating effects of chronic treatment with duloxetine (10, 20 and 25 mg/kg/day, p.o. for 21 days) and FST swimming time (sec.) in the Wister rats exposed to chronic restraint stress (CRS).	112
Fig. (29)	Pearson's correlation between the prefrontal cortical BDNF level induced by duloxetine (10, 20 and 25 mg/kg/day, p.o. for 21 days) and the swimming time in Wistar rats exposed to chronic restraint stress (CRS).	113
Fig. (30)	A bar chart illustrating effects of chronic treatment with duloxetine (10, 20 and 25 mg/kg/day, p.o. for 21 days) on FST climbing time (sec.) the Wister rats exposed to chronic restraint stress (CRS).	114
Fig. (31)	Pearson's correlation between the prefrontal cortical BDNF level induced by duloxetine (10, 20 and 25 mg/kg/day, p.o. for 21 days) on the climbing time in Wistar rats exposed to chronic restraint stress (CRS).	115

Figure	Title	Page
Fig. (۳۲)	A bar chart illustrating effects of chronic treatment with duloxetine (۱۰, ۲۰ and ۳۰ mg/kg/day, p.o. for ۲۱ days) on open field test (OFT) frequency of rearing in Wistar rats exposed to chronic restraint stress (CRS).	۱۲۲
Fig. (۳۳)	A bar chart illustrating effects of chronic treatment with duloxetine (۱۰, ۲۰ and ۳۰ mg/kg/day, p.o. for ۲۱ days) on open field test (OFT) number of crossed squares rearing in Wistar rats exposed to chronic restraint stress (CRS).	۱۲۶
Fig. (۳۴)	A bar chart illustrating effects of chronic treatment with duloxetine (۱۰, ۲۰ and ۳۰ mg/kg/day, p.o. for ۲۱ days) on open field test (OFT) time in central zone (sec.) in Wistar rats exposed to chronic restraint stress (CRS).	۱۲۹
Fig. (۳۵)	A bar chart illustrating effects of chronic treatment with duloxetine (۱۰, ۲۰ and ۳۰ mg/kg/day, p.o. for ۲۱ days) on percentage body weight changes in Wistar rats exposed to chronic restraint stress (CRS).	۱۳۳

List of Tables

Table	Title	Page
Tab. (1)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on serum corticosterone concentrations (ng/ml) in Wistar rats exposed to chronic restraint stress (CRS).	72
Tab. (2)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on BDNF concentration in tissue homogenate of prefrontal cortex in Wistar rats exposed to chronic restraint stress (CRS).	75
Tab. (3)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on BDNF concentration (ug/mg protein) in tissue homogenate of hippocampus in Wistar rats exposed to chronic restraint stress (CRS).	79
Tab. (4)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on FST immobility time (sec.) in Wistar rats exposed to chronic restraint stress (CRS).	110
Tab. (5)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on FST swimming time (sec.) in Wistar rats exposed to chronic restraint stress (CRS).	113
Tab. (6)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on FST climbing time (sec.) in Wistar rats exposed to chronic restraint stress (CRS).	117

Table	Title	Page
Tab. (v)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on open field test (OFT) frequency of rearing in Wistar rats exposed to chronic restraint stress (CRS).	121
Tab. (vi)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on open field test (OFT) number of crossed squares rearing in Wistar rats exposed to chronic restraint stress (CRS).	124
Tab. (vii)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on open field test (OFT) time in central zone (sec.) in Wistar rats exposed to chronic restraint stress (CRS).	127
Tab. (viii)	Effects of chronic treatment with duloxetine (10, 20 and 40 mg/kg/day, p.o. for 21 days) on % body weight change in Wistar rats exposed to chronic restraint stress (CRS).	131

List of Abbreviations

Abb.	Meaning
•-HT	•-hydroxy tryptamine
ADHD	Attention deficit hyperactivity disorders
BDNF	Brain derived neurotropic factor
BSA	Bovine serum albumin
CA	Cornu Ammonis
C _{max}	Maximum plasma concentration
CORT	Corticosterone
CRS	Chronic restraint stress
CYP ¹ A ²	Cytochrome P ¹ A ²
CYP ² D ¹	Cytochrome P ² D ¹
CYP- ² C ⁸	Cytochrome P ² C ⁸
D.P.X.	Di-N- Butyl phthalate in Xylene
DPNP	Diabetic peripheral neuropathic pain
DSM IV-TR	Diagnostic statistical manual IV Text revised
ELISA	Enzyme-linked immunosorbent assay
FDA	Food and Drug Administration
FST	Forced swimming test
GABA	Gama aminobutyric acid
GAD	Generalized anxiety disorder
GR	Glucocorticoid receptors
HEPES	N- ² -Hydroxy Ethyl Piperazine–N ¹ - ² -
HPA	Hypothalamic-pituitary-adrenal axis
HRP	Horseradish Peroxidase
ICD	International classification of disease